Supernus Pharmaceuticals (SUPN) Cash from Operations (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Cash from Operations data on file, last reported at 66524000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 117.41% year-over-year to 66524000.0 in Q1 2026; TTM through Mar 2026 was 83256000.0, a 49.28% decrease from a year earlier, with the FY2025 full-year figure at 47331000.0, down 72.47% from the prior year.
• Cash from Operations for Q1 2026 stood at 66524000.0, up from 19861000.0 in the prior quarter.
• Over the last five years, Cash from Operations for SUPN reached as high as 71119000.0 in Q2 2022 and fell as low as 61664000.0 in Q3 2025.
• Historically, Cash from Operations has averaged 30218647.06 across 5 years, with a median of 35875000.0 in 2023.
• Across the five-year window, Cash from Operations soared 1041.93% in 2023 and tumbled 215.22% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 27564000.0 in 2022, then jumped by 63.1% to 44958000.0 in 2023, then fell by 1.23% to 44406000.0 in 2024, then sank by 55.27% to 19861000.0 in 2025, then jumped by 234.95% to 66524000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 66524000.0 in Q1 2026, 19861000.0 in Q4 2025, and 61664000.0 in Q3 2025.